Clinical Impact of Bisoprolol Versus Carvedilol in Patients Undergoing Femoropopliteal Stenting

Soga, Yoshimitsu; Iida, Osamu; Suzuki, Kenji; Hirano, Keisuke; Kawasaki, Daizo; Shintani, Yoshiaki; Suematsu, Nobuhiro; Yamaoka, Terutoshi; Tsuchiya, Taketsugu; Miyashita, Yusuke; Okazaki, Shinya; Shinozaki, Norihiko; Takahashi, Hitomi

doi:10.5551/jat.21121

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2020

Publication Types

Select...

Article4

Relationship

Self Cite2

Independent2

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it has been reported that intensive medical therapy was associated with good survival and fewer major adverse limb events. [23][24][25] In the present study, the usage rates of statin, angiotensin-converting enzyme/angiotensin receptor blocker, and beta blockers were 47%, 62%, and 31%, respectively, which were considered insufficient. To improve the survival rate of high-risk CLI patients, careful attention to their medical status must be given.…”

Section: Discussionmentioning

confidence: 63%

Prognosis of critical limb ischemia patients with tissue loss after achievement of complete wound healing by endovascular therapy

Kobayashi

Hirano

Ito

et al. 2015

Journal of Vascular Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 63%

Prognosis of critical limb ischemia patients with tissue loss after achievement of complete wound healing by endovascular therapy

Kobayashi

Hirano

Ito

et al. 2015

Journal of Vascular Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

A Soluplus/Poloxamer 407-based self-nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability

Han

Peng

et al. 2020

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

The role of b-blockers in the new revision of the 2018 European guidelines for the diagnosis and treatment of arterial hypertension in the patients with comorbidities

et al. 2018

View full text Add to dashboard Cite

The review from the standpoint of the newest European guidelines for the diagnosis and treatment of arterial hypertension discusses the role of highly selective b-blockers and, above all, the superior member of these drugs - bisoprolol in blood pressure lowering therapy in comorbid patients with arterial hypertension. In terms of evidence-based medicine, the benefits of bisoprolol in patients with comorbid coronary heart disease, chronic heart failure, atrial fibrillation, and aortic pathology are discussed. The data on the feasibility and the possibility of including in the therapy highly selective b-adrenergic blockers in patients with chronic obstructive pulmonary disease, peripheral artery disease, diabetes and sexual dysfunction are presented

show abstract

Clinical Impact of Bisoprolol Versus Carvedilol in Patients Undergoing Femoropopliteal Stenting

Cited by 4 publications

References 32 publications

Prognosis of critical limb ischemia patients with tissue loss after achievement of complete wound healing by endovascular therapy

Prognosis of critical limb ischemia patients with tissue loss after achievement of complete wound healing by endovascular therapy

A Soluplus/Poloxamer 407-based self-nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability

The role of b-blockers in the new revision of the 2018 European guidelines for the diagnosis and treatment of arterial hypertension in the patients with comorbidities

Contact Info

Product

Resources

About